Literature DB >> 9310356

Destabilization, oligomerization and inhibition of the mitogenic activity of acidic fibroblast-growth factor by aurintricarboxylic acid.

R M Lozano1, G Rivas, G Giménez-Gallego.   

Abstract

The triphenylmethane derivative aurintricarboxylic acid has been used to inhibit angiogenesis, vascular smooth muscle cell proliferation and cell transformation, an effect that has been attributed to its relatively nonspecific inhibitory activity of protein-nucleic acid interactions. Here, we show that this compound binds to acidic fibroblast growth factor, a prototypic member of a family of protein mitogens activated by heparin, altering its physicochemical properties and decreasing its mitogenic activity. Counteraction of the effects of aurintricarboxylic acid by heparin shows that the two compounds have opposite and reversible effects on acidic fibroblast growth factor structure and biological activity. The studies reported here may contribute to a deeper understanding of the inhibition of fibroblast-growth-factor-dependent mitogenesis of relevance to future pharmacologic developments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310356     DOI: 10.1111/j.1432-1033.1997.t01-2-00030.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  3 in total

1.  Aurintricarboxylic acid inhibits complement activation, membrane attack complex, and choroidal neovascularization in a model of macular degeneration.

Authors:  Erion Lipo; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-29       Impact factor: 4.799

Review 2.  Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends.

Authors:  Giancarlo Ghiselli
Journal:  Medicines (Basel)       Date:  2019-07-29

3.  Gene expression-based screening for inhibitors of PDGFR signaling.

Authors:  Alena A Antipova; Brent R Stockwell; Todd R Golub
Journal:  Genome Biol       Date:  2008-03-01       Impact factor: 13.583

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.